Uvax Bio

Uvax Bio

Biotechnology, 660 W Germantown Pike, Newark, Delaware, 19462, United States, 11-50 Employees

uvaxbio.com

  • LinkedIn

Who is UVAX BIO

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform...

Read More

map
  • 660 W Germantown Pike, Newark, Delaware, 19462, United States Headquarters: 660 W Germantown Pike, Newark, Delaware, 19462, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from UVAX BIO

Uvax Bio Org Chart and Mapping

Employees

Cyril Empig

Lead, Non-Clinical Studies

Benjamin Wang

Business Development Associate

Kevin O'Neill

Senior Vice President, Corporate Strategy

Matthijs Schoots

Chief of Staff, Head Strategic Planning

Ke Li

Vice President, Vaccine Development and Technical Ops

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Uvax Bio

Answer: Uvax Bio's headquarters are located at 660 W Germantown Pike, Newark, Delaware, 19462, United States

Answer: Uvax Bio's official website is https://uvaxbio.com

Answer: Uvax Bio's revenue is $250 Million to $500 Million

Answer: Uvax Bio's SIC: 2834

Answer: Uvax Bio's NAICS: 541714

Answer: Uvax Bio has 11-50 employees

Answer: Uvax Bio is in Biotechnology

Answer: Uvax Bio contact info: Phone number: Website: https://uvaxbio.com

Answer: Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access